Lung Cancer | Specialty

Next Steps for RET Fusion+ NSCLC

November 16th 2020

RET Fusion+ NSCLC and COVID-19

November 16th 2020

Intracranial Response Rates from RET Inhibitors

November 16th 2020

Importance of Frontline RET Inhibition in NSCLC

November 16th 2020

FDA Approval of RET Inhibitors in NSCLC

November 16th 2020

Best Practices for NGS Selection in NSCLC

November 16th 2020

Use of Liquid Biopsy for RET Detection

November 16th 2020

Optimal Detection of RET Fusions

November 16th 2020

Multikinase TKIs for RET Fusion+ NSCLC

November 16th 2020

Biology of RET Genetic Alterations

November 16th 2020

Pembrolizumab Shows Intriguing Benefit in Leptomeningeal Metastasis From Solid Tumors

November 12th 2020

November 12, 2020 — Pembrolizumab led to a 38% central nervous system response rate and was well tolerated in patients with leptomeningeal metastasis from solid tumors. However, the study was closed early due to poor accrual.

DLL3-Directed BiTE, AMG 757 Shows Early Tolerability and Efficacy in Small Cell Lung Cancer

November 12th 2020

November 12, 2020 - AMG 757, a DLL3-directed, half-life extended bispecific T-cell engager, was shown to have a feasible adverse effect profile in patients with small cell lung cancer.

Adagrasib Shows Early Efficacy in KRAS G12C-Mutant NSCLC and CRC

November 11th 2020

Adagrasib, a novel agent aimed at KRAS G12C mutations, has demonstrated early signs of efficacy in patients with advanced non–small cell lung cancer and colorectal cancer whose tumors harbor the alteration, raising hopes for a new therapy against a challenging oncogenic target.

Growth of Targeted Therapy Requires More Nuanced Treatment Considerations in NSCLC

November 11th 2020

D. Ross Camidge, MD, PhD discusses the role of targeted therapy and how it is rapidly expanding in the treatment paradigm of patients with non–small cell lung cancer.

Leveraged Modalities are Leading to Improved Survival in EGFR+ NSCLC

November 11th 2020

November 11, 2020 - Rao Mushtaq, MD, provides perspective on these pivotal data in EGFR-mutant non–small cell lung cancer.

Chemoimmunotherapy Remains Best Choice for Some PD-L1–High Lung Cancers

November 10th 2020

November 10, 2020 - Nasser Hanna, MD, discusses immunotherapy and, although, it may be the right therapy for most patients with lung cancer expressing PD-L1 greater than or equal to 50%, for those who are at risk for cancer-related morbidity with early progressive disease, chemoimmunotherapy may be the more appropriate choice.

Updated Data Solidify First- and Second-Line Standards in Extensive-Stage Small Cell Lung Cancer

November 10th 2020

Haiying Cheng, MD, PhD highlights new data from key clinical trials in extensive-stage small cell lung cancer.

KEYNOTE-598 Trial Examining Pembrolizumab/Ipilimumab in NSCLC Stopped for Futility

November 10th 2020

The phase 3 KEYNOTE-598 trial evaluating the dual immunotherapy combination comprised of pembrolizumab and ipilimumab as frontline treatment in patients with metastatic non–small cell lung cancer who have a PD-L1 tumor proportion score of 50% or greater and do not harbor any EGFR or ALK aberrations has been discontinued.

MET, RET, and TRK Inhibitors Achieve Standard-of-Care Status in Lung Cancer

November 9th 2020

Alterations in MET, RET, and NTRK have become established actionable drivers of oncogenesis in lung cancer, and therapeutics targeting these aberrations have since obtained regulatory approval from the FDA and have been incorporated into treatment guidelines.

KRAS G12C Emerges as an Actionable Alteration in NSCLC

November 9th 2020

Although historically considered to be undruggable, the KRAS G12C mutation has since emerged as an actionable alteration in the field of non–small cell lung cancer.